13.44
13.44 (0%)
As of Feb 14, 2025
Entrada Therapeutics, Inc. [TRDA]
Source:
Company Overview
Entrada Therapeutics, Inc is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines which engage intracellular targets that have long been considered inaccessible.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | ( 857 ) 520-9158 |
| Industry | manufacturing |
| CEO | Dipal Doshi |
| Website | www.linkedin.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $210.8 |
| Operating Profit | $47 |
| Net Income | $65.6 |
| Net Cash | $33.6 |
Profit Ratios
| Gross Margin | $210.8 |
| Operating Margin | 22.3 |
| Profit as % of Revenues | 321.2% |
| Profit as % of Assets | 13.2% |
| Profit as % of Stockholder Equity | 15.3% |
Management Effectiveness
| Return on Equity | 15.3% |
| Return on Assets | 12.5% |
| Turnover Ratio | 42.4% |
| EBITA | $47 |
Balance Sheet and Cash Flow Measures
| Total Assets | $526.3 |
| Total Liabilities | $97.6 |
| Operating Cash Flow | $-41.6 |
| Investing Cash Flow | $-27.8 |
| Financing Cash Flow | $103 |
